Literature DB >> 23417511

Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.

B Michael Silber1, Satish Rao, Kimberly L Fife, Alejandra Gallardo-Godoy, Adam R Renslo, Deepak K Dalvie, Kurt Giles, Yevgeniy Freyman, Manuel Elepano, Joel R Gever, Zhe Li, Matthew P Jacobson, Yong Huang, Leslie Z Benet, Stanley B Prusiner.   

Abstract

PURPOSE: To discover drugs lowering PrP(Sc) in prion-infected cultured neuronal cells that achieve high concentrations in brain to test in mouse models of prion disease and then treat people with these fatal diseases.
METHODS: We tested 2-AMT analogs for EC50 and PK after a 40 mg/kg single dose and 40-210 mg/kg/day doses for 3 days. We calculated plasma and brain AUC, ratio of AUC/EC50 after dosing. We reasoned that compounds with high AUC/EC50 ratios should be good candidates going forward.
RESULTS: We evaluated 27 2-AMTs in single-dose and 10 in 3-day PK studies, of which IND24 and IND81 were selected for testing in mouse models of prion disease. They had high concentrations in brain after oral dosing. Absolute bioavailability ranged from 27-40%. AUC/EC50 ratios after 3 days were >100 (total) and 48-113 (unbound). Stability in liver microsomes ranged from 30->60 min. Ring hydroxylated metabolites were observed in microsomes. Neither was a substrate for the MDR1 transporter.
CONCLUSIONS: IND24 and IND81 are active in vitro and show high AUC/EC50 ratios (total and unbound) in plasma and brain. These will be evaluated in mouse models of prion disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417511      PMCID: PMC3640342          DOI: 10.1007/s11095-012-0912-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  40 in total

1.  Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa.

Authors:  A R Hilgers; R A Conradi; P S Burton
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

2.  Spongiform encephalopathies. The prion's progress.

Authors:  C Weissmann
Journal:  Nature       Date:  1991-02-14       Impact factor: 49.962

3.  Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons.

Authors:  Vera Novitskaya; Olga V Bocharova; Igor Bronstein; Ilia V Baskakov
Journal:  J Biol Chem       Date:  2006-03-22       Impact factor: 5.157

4.  Characterization of scrapie infection in mouse neuroblastoma cells.

Authors:  R E Race; L H Fadness; B Chesebro
Journal:  J Gen Virol       Date:  1987-05       Impact factor: 3.891

5.  Changing patterns of kuru: epidemiological changes in the period of increasing contact of the Fore people with western civilization.

Authors:  M Alpers; D C Gajdusek
Journal:  Am J Trop Med Hyg       Date:  1965-09       Impact factor: 2.345

Review 6.  Prions and neurodegenerative diseases.

Authors:  S B Prusiner
Journal:  N Engl J Med       Date:  1987-12-17       Impact factor: 91.245

7.  Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils.

Authors:  Aneta T Petkova; Richard D Leapman; Zhihong Guo; Wai-Ming Yau; Mark P Mattson; Robert Tycko
Journal:  Science       Date:  2005-01-14       Impact factor: 47.728

8.  Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome.

Authors:  K Hsiao; H F Baker; T J Crow; M Poulter; F Owen; J D Terwilliger; D Westaway; J Ott; S B Prusiner
Journal:  Nature       Date:  1989-03-23       Impact factor: 49.962

9.  Identification of prion amyloid filaments in scrapie-infected brain.

Authors:  S J DeArmond; M P McKinley; R A Barry; M B Braunfeld; J R McColloch; S B Prusiner
Journal:  Cell       Date:  1985-05       Impact factor: 41.582

10.  Novel proteinaceous infectious particles cause scrapie.

Authors:  S B Prusiner
Journal:  Science       Date:  1982-04-09       Impact factor: 47.728

View more
  15 in total

1.  Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice.

Authors:  Duo Lu; Kurt Giles; Zhe Li; Satish Rao; Elena Dolghih; Joel R Gever; Michal Geva; Manuel L Elepano; Abby Oehler; Clifford Bryant; Adam R Renslo; Matthew P Jacobson; Stephen J Dearmond; B Michael Silber; Stanley B Prusiner
Journal:  J Pharmacol Exp Ther       Date:  2013-08-21       Impact factor: 4.030

2.  Drug resistance confounding prion therapeutics.

Authors:  David B Berry; Duo Lu; Michal Geva; Joel C Watts; Sumita Bhardwaj; Abby Oehler; Adam R Renslo; Stephen J DeArmond; Stanley B Prusiner; Kurt Giles
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-15       Impact factor: 11.205

3.  Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease.

Authors:  Simon Mead; Matthew Burnell; Jessica Lowe; Andrew Thompson; Ana Lukic; Marie-Claire Porter; Christopher Carswell; Diego Kaski; Janna Kenny; Tze How Mok; Nina Bjurstrom; Edit Franko; Michele Gorham; Ronald Druyeh; Jonathan D F Wadsworth; Zane Jaunmuktane; Sebastian Brandner; Harpreet Hyare; Peter Rudge; A Sarah Walker; John Collinge
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

Review 4.  Developing Therapeutics for PrP Prion Diseases.

Authors:  Kurt Giles; Steven H Olson; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

5.  Prion and Prion-like Diseases in Humans: Poster Abstracts.

Authors: 
Journal:  Prion       Date:  2013 Apr/May       Impact factor: 3.931

6.  Use of a 2-aminothiazole to Treat Chronic Wasting Disease in Transgenic Mice.

Authors:  David Berry; Kurt Giles; Abby Oehler; Sumita Bhardwaj; Stephen J DeArmond; Stanley B Prusiner
Journal:  J Infect Dis       Date:  2015-07-15       Impact factor: 5.226

7.  Different 2-Aminothiazole Therapeutics Produce Distinct Patterns of Scrapie Prion Neuropathology in Mouse Brains.

Authors:  Kurt Giles; David B Berry; Carlo Condello; Ronald C Hawley; Alejandra Gallardo-Godoy; Clifford Bryant; Abby Oehler; Manuel Elepano; Sumita Bhardwaj; Smita Patel; B Michael Silber; Shenheng Guan; Stephen J DeArmond; Adam R Renslo; Stanley B Prusiner
Journal:  J Pharmacol Exp Ther       Date:  2015-07-29       Impact factor: 4.030

8.  2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease.

Authors:  Zhe Li; B Michael Silber; Satish Rao; Joel R Gever; Clifford Bryant; Alejandra Gallardo-Godoy; Elena Dolghih; Kartika Widjaja; Manuel Elepano; Matthew P Jacobson; Stanley B Prusiner; Adam R Renslo
Journal:  ChemMedChem       Date:  2013-03-18       Impact factor: 3.466

9.  Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice.

Authors:  Kurt Giles; David B Berry; Carlo Condello; Brittany N Dugger; Zhe Li; Abby Oehler; Sumita Bhardwaj; Manuel Elepano; Shenheng Guan; B Michael Silber; Steven H Olson; Stanley B Prusiner
Journal:  J Pharmacol Exp Ther       Date:  2016-06-17       Impact factor: 4.030

10.  Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.

Authors:  B Michael Silber; Joel R Gever; Zhe Li; Alejandra Gallardo-Godoy; Adam R Renslo; Kartika Widjaja; John J Irwin; Satish Rao; Matthew P Jacobson; Sina Ghaemmaghami; Stanley B Prusiner
Journal:  Bioorg Med Chem       Date:  2013-09-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.